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Abstract
Background: Heparin-induced thrombocytopenia (HIT) is a thromboembolic complication that can occur with
unfractionated heparin (UFH) or low molecular weight heparin (LMWH). Our objective was to determine and
compare the incidence of IgG-class HIT antibodies in patients undergoing total hip arthroplasty (THA) or total knee
arthroplasty (TKA) with different antithrombotic prophylaxis therapies and their contributions to the occurrence of
venous thromboembolism (VTE).
Methods: A prospective observational study was performed for 374 Japanese patients undergoing THA or TKA to
determine the incidence of VTE. IgG-class anti-PF4/heparin antibodies were measured using IgG-specific EIA before
and after the operation.
Results: In the clinical outcome, the incidence of symptomatic deep vein thrombosis (DVT) was 15.0% (56/374,
TKA; 35, THA; 21) and pulmonary emboli (PE) were not observed. The total seroconversion incidence of IgG-class
PF4/heparin antibodies was 19.8% (74/374). The seroconversion incidence of IgG-class PF4/heparin antibodies was
higher in patients receiving UFH (32.7%) compared to those receiving LMWH (9.5%) or fondaparinux (14.8%).
Furthermore, the seroconversion incidence was significantly higher in patients undergoing TKA compared to those
undergoing THA. Based on multivariate analysis, seroconversion of the IgG-class PF4/heparin antibodies was
independent a risk factor for symptomatic DVT.
Conclusion: Our findings show that the seroconversion of IgG-class anti-PF4/heparin antibodies differed with
various anti-thrombotic prophylaxis therapeutics and was associated with the risk of DVT in a subset of patients
undergoing total joint arthroplasty (TKA and THA).
Background
Venous thromboembolism (VTE) is a serious complica-
tion of major orthopedic surgery including total hip
arthroplasty (THA) and total knee arthroplasty (TKA)
[1]. The incidence of postoperative deep vein thrombo-
sis (DVT) is 45-57% after THA and 41-85% after TKA if
prophylaxis is not used [2]. Consequently, pharmacolo-
gical thromboprophylaxis is recommended and widely
used in patients undergoing orthopedic surgery [3].
Although, low-dose unfractionated heparin (UFH) has
been used as a thromboprophylactic agent, enoxaparin
and fondaparinux have recently been approved for
thromboprophylaxis in patients after TKA or THA in
Japan [4,5]. LMWHs is an important tool in DVT man-
agement, offering advantages over UFH, considering the
reduced risk for HIT [6], a prothrombotic adverse drug
reaction caused by platelet-activating antibodies that
recognize the complex of platelet factor 4 (PF4) bound
to heparin [7]. Indeed, HIT is found in approximately
5% of patients receiving unfractionated heparin
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By contrast, a reduced risk of HIT has been confirmed
in patients receiving LMWH or fondaparinux [9]. HIT
is caused by the generation of heparin-dependent anti-
bodies against the PF4/heparin complex, which cause
platelet activation and aggregation and eventually pro-
gress to thrombocytopenia and thrombosis [10]. Recent
studies have confirmed a minor role of IgM- and IgA-
class anti-PF4/heparin antibodies in HIT [11,12] and
there is growing evidence that only antibodies of the
IgG class are capable of inducing platelet activation [13].
The aim of the present study was to determine the risk
factors of VTE, and the incidence of symptomatic DVTs
and PEs in patients undergoing THA or TKA under
pharmacologic prophylaxis. Furthermore, in this study,
we used a specific immunoassay that detects only IgG-
class anti-PF4/heparin antibodies to determine the fre-
quency of these antibodies and their contributions to
the occurrence of VTEs.
Methods
Patients
All patients who underwent THA or TKA at our institu-
tion between September 1 2006, and April 30 2010,
were enrolled in this study to determine the incidence
of PE and symptomatic DVT. Data were collected
regarding baseline patient characteristics, including age,
gender, underlying disease and VTE risk factors (pre-
vious thrombosis, malignancy, diabetes, hypertension,
hyperlipidemia and arrhythmia). Bleeding was defined as
overt if it was clinically evident and there was a clear
source of bleeding. None of the patients had any history
of previous heparin exposure within the past 90 days.
The study protocol was approved by the Ethics Com-
mittees of the Nagasaki Medical Center and written
informed consent was obtained from each patient.
Thromboprophylaxis Regimen
Our institution has used unfractionated heparin (UFH)
since 2004. Patients received 1000 units of UFH via a sin-
gle bolus intravenous injection during the operation and
5000 units of UFH via drip intravenous infusion (24 hr)
on post-operative day 2. Since June 2007, fondaparinux
and enoxaparin have been approved for post-operative
thromboprophylaxis in Japan. Four months later, we
changed the thromboprophylactic regimen to fondapari-
nux or enoxaparin in our institute. Fondaparinux (2.5 mg
once a day) or enoxaparin (2,000 IU twice a day) were
injected subcutaneously for 10 days. The operation was
performed under general anesthesia in all cases. In TKA,
air tourniquent was used during operation in all cases.
All TKAs were performed with a cemented component.
THAs were almost performed with a cementless femoral
stem and an acetabular component. A foot pump (A-V
Impulse System, Novamedix Corp, Hampshire, UK) and
compression stockings were initiated on day 1 in all
subjects.
Detection of DVT/PE
After the operation, primary screening for VTE was
undertaken by meticulous observation of the clinical
signs, and determination of plasma D-dimer levels. For
the clinical signs of DVT-PE, we carefully examined the
patient for swelling of the entire leg or localized leg swel-
ling, acute cardiovascular dysfunction, dyspnea and chest
pain. Patients who exhibited high plasma concentrations
of D-dimer >10 μg/ml, or were suspected to exhibit the
clinical signs of DVT were subjected to CT scanning
using MDCT from the chest to the ankle and venous
Doppler ultrasonography for detection of DVT/PE.
Blood sampling
Serum samples were collected before the operation and
at postoperative day 7, and stored at -70°C. A sandwich
ELISA kit (GTI Diagnostics, Waukesha, WI) was used
to measure the IgG-class anti-heparin-PE4 antibody
(HIT Ab) titer of the serum according to the manufac-
turer’s instructions. The microtiter wells were precoated
with polyvinylsulfonate-PF4 complexes. Antibodies
bound to polyvinylsulfonate-PF4 were identified by affi-
nity-purified anti-human IgG peroxidase conjugate.
ELISA reactivities (optical density, OD) are expressed
relative to a standard control. Positive and negative con-
trols were included in every plate. The samples with
readings ≥0.40 absorbance units were considered posi-
tive according to the manufacturer’s instructions. While
the results of the ELISA test merely confirmed the pre-
sence of HIT antibodies, HIT was defined as a >50%
reduction in the platelet count or an absolute platelet
count <10
5/μl during and after heparin treatment, with
no other cause of thrombocytopenia, and a positive
result in the HIT antibody test [14].
Assessment of bleeding
During this study, the patients were examined daily for
any evidence of wound hematoma, as well as other
manifestations of bleeding. Bleeding was considered to
be major if there was a wound hematoma necessitating
surgical revision, gastrointestinal bleeding, or any bleed-
ing requiring transfusion of more than 400 ml of blood
and interruption of prophylaxis.
Statistical Analysis
Crude associations for categorical variables were evaluated
using a Chi-squared test. For continuous variables, differ-
ences between groups were evaluated by Mann-Whitney
U test. Multivariate analysis was conducted by fitting logis-
tic regression analysis models to adjust for the effects of
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of DVT. The variables on multiple logistic regression ana-
lysis were selected from variables showing a p value <0.1
in univariate analyses. The exact confidence intervals and
probability values are reported for the multivariate models.
For all other tests, a p value <0.05 was considered statisti-
cally significant. All statistical analysis was performed with
SPSS version 13.0 (Chicago, IL, USA). Odds ratios (OR)
for regression modeling and their 95% confidence intervals
(CI) are reported.
Result
Clinical outcome
Occurrence of VTE
The total joint arthroplasty (TKA and THA) were per-
formed and the distributions of the patient’s mean age
and gender are presented in Table 1. Two hundred and
fourteen patients (57.2%) underwent THA and 160
patients (42.8%) underwent TKA. For pharmacological
VTE prophylaxis, unfractionated heparin (UFH), low
molecular-weight heparin (LMWH; enoxaparin) and
fondaparinux were administered in 27.8%, 25.4% and
21.7% of the total patients respectively. The primary
diagnosis was osteoarthritis in 89.7% and 80.6% of the
patients who underwent THA and TKA, respectively.
Pulmonary emboli did not occur in this study. As
shown in Table 2, symptomatic DVT was observed in
21 patients undergoing THA (9.8%) and 35 patients
undergoing TKA (21.9%). All of the DVTs were the dis-
tal type.
Occurrence of bleeding
Twenty (5.3%) of the 374 operations were associated
with major bleeding (Table 2). These complications did
not influence the patient’s ultimate outcome. There
were no gastrointestinal bleeding events.
Seroconversion of IgG-class PF4/heparin antibody
The seroconversion of IgG-class PF4/heparin antibody
was confirmed in 27.5% (44/160) of patients undergoing
Table 1 Patients characteristics
Characteristics THA TKA p
n = 214 n = 160
Age 65.6 ± 11.7 (25-90) 73.9 ± 8.9 (30-89) <0.00001
Age≧75 yr 49 89 <0.00001
Age < 75 yr 165 71
Gender(male/female) 34/180 31/129 0.379
BMI(Kg/m
2) 24.1 ± 3.8 (15.1-37.7) 25.9 ± 4.3 (13.7-41.4) <0.00001
BMI≧30 17 30 0.002
BMI < 30 197 130
Risk factors 102/214 (47.7%) 112/160 (70.0%) <0.00001
OA/RA 192/22 129/31 0.013
Seroconvertion of IgG-class Anti-PF4/heparinAb 30/214 (14.0%) 44/160 (27.5%) 0.001
Treatment
UFH 60/214 (28.0%) 44/160 (27.5%) 0.909
LMWH 64/214 (29.9%) 31/160 (19.4%) 0.021
Fondaparinux 49/214 (22.9%) 32/160 (20.0%) 0.501
Others 21/214 (9.8%) 29/160 (18.1%) 0.019
Aspirin 16/214 (7.5%) 27/160 (16.9%)
Warfarin 4/214 (1.9%) 1/160 (0.6%)
Cilostazol 14/214 (6.5%) 23/160 (14.4%)
No medication 20/214 (9.3%) 24/160 (15.0%) 0.093
Abbreviations: BMI; body mass index, TKA; total knee arthroplasty, THA; total hip arthroplasty, OA; osteoarthritis, RA; rheumatoid arthritis, UFH; unfractionated
heparin, LMWH; low-molecular weight heparin.
Table 2 Incidence of DVT and major bleeding
THA/
TKA
drug No.
patients
No. DVT
(%)
No. bleeding
(%)
THA UFH 60 6(10.0) 3(5.0)
LMWH 64 6(9.4) 1(1.6)
Fondaparinux 49 4(8.2) 3(6.1)
others 41 5(12.2) 1(2.4)
TKA UFH 44 10(22.7) 5(11.4)
LMWH 31 8(25.8) 2(6.5)
Fondaparinux 32 4(12.5) 0(0)
others 53 13(24.5) 5(9.4)
Abbreviations: DVT; deep vein thrombosis, TKA; total knee arthroplasty, THA;
total hip arthroplasty, UFH; unfractionated heparin, LMWH; low-molecular
weight heparin.
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(Table 3). The incidence of seroconversion of IgG-class
PF4/heparin antibodies was significantly higher in
patients undergoing TKA compared to those undergoing
THA. The seroconversion of IgG-class PF4/heparin
antibodies varied with the different thromboembolic
prophylaxis therapeutics. The conversion incidence of
IgG-class PF4/heparin antibodies was significantly lower
in patients receiving fondaparinux compared with those
receiving UFH. Interestingly, seroconversion of IgG-class
PF4/heparin antibodies was demonstrated in patients
who did not receive UFH, LWMH or fondaparinux.
Platelet count
We compared the platelet counts before the operation and
at post-operative day 7 in the patients with or without ser-
oconversion of IgG-class PF4/heparin antibodies. Platelet
counts were elevated significantly at post-operative day 7
in the presence or absence of seroconversion of IgG-class
PF4/heparin antibodies and none of these patients devel-
oped HIT (Figure 1).
Risk factors for DVT
In comparisons between patients with or without DVT,
several variables were selected through univariate analy-
sis, based upon a p-value <0.1 (Table 4), and these
selected parameters were then subjected to multivariate
analysis. The parameters included were; age, gender, the
type of operation (TKA/THA), and postoperative
(7 days) seroconversion of IgG PF4/heparin antibody.
Logistic regression multivariate analysis revealed older
age (≧75 yr), female gender and seroconversion of the
IgG anti-PF4/heparin antibody as significant indepen-
dent risk factors (Table 5).
Next, we determined whether seroconversion of the
IgG-class HIT antibody contributed to the occurrence
of DVT in the subgroups receiving the same antithrom-
botic prophylaxis agent (Table 6). Seroconversion of the
IgG-class HIT antibody was significantly associated with
the occurrence DVT in patients receiving UFH (p =
0.001, OR; 6.2). Meanwhile, seroconversion of the
IgG-class HIT antibody was not associated with the
occurrence of DVT in patients receiving LMWH or fon-
daparinux, as well as in patients who were not treated
with these prophylaxes.
Discussion
In this report we describe our studies comparing the
incidence of anti-PF4/heparin antibodies in patients
receiving different thromboprophylaxis therapeutics
after total joint arthroplasty (TKA and THA). Previous
study has reported a significant difference in HIT
between unfractionated heparin (UFH) and LMWH in
postoperative orthopedic patients, suggesting that
LMWH is safer than UFH in these patients [9,15]. Our
hypothesis was that the frequencies of seroconversion of
IgG-class anti-PF4/heparin would be reduced in patients
receiving fondaparinux, and even in those receiving
LMWHs, and we focused on the relationship between
seroconversion of these antibodies and the occurrence
of symptomatic DVT under different anti-thrombotic
prophylaxis therapeutics. We found that seroconversion
of the IgG-class anti-PF4/heparin antibody occurred in a
significant number of patients and that it occurred more
often in post-operative patients receiving UFH com-
pared with those receiving fondaparinux or LMWH.
Furthermore, we demonstrated that seroconversion of
the IgG-class anti-PF4/heparin antibody could be an
independent risk factor of symptomatic DVT in the
absence of thrombocytopenia. Our data also demon-
strated that older age (≧75 yr) is an independent risk
factor of symptomatic DVT. Old age has already been
demonstrated to be an important risk factor for VTE
[3]. Our result seems to support these previous findings.
HIT is caused by heparin-dependent IgG-class antibo-
dies against the PF4/heparin complex. These IgG
immune-complexes bind to the platelet surface, result-
ing in platelet activation and aggregation [16]. Immune
assays for PF4/heparin antibody generally detect antibo-
dies of all classes Igs (IgG, A, and IgM) [12]. Accord-
ingly, these immune assays can be expected to display
much lower specificity, since only antibodies of the IgG
class against PF4/heparin complex can activate platelets
[13]. Therefore, in this prospective study, we used an
IgG-specific EIA to improve the specificity for the anti-
PF4/heparin antibody compared with the global assay.
The diagnosis of HIT is based on clinical criteria,
including thrombocytopenia, which is confirmed by in
vitro demonstration of anti-PF4/heparin antibodies
using functional and immunological methods [17].
Table 3 Analysis of IgG-class anti-PF4/heparin antibody
seroconversion rate
THA/
TKA
drug No.
patients
No. seroconversion
(%)
Total(%)
THA UFH 60 17(28.3) 30(14.0)
LMWH 64 4(6.3)*
Fondaparinux 49 4(8.2)**
others 41 5(12.2)
TKA UFH 44 17(38.6) 44(27.5)
****
LMWH 31 5(16.1)***
Fondaparinux 32 8(25.0)
others 53 14(26.4)
Abbreviations: TKA; total knee arthroplasty, THA; total hip arthroplasty, UFH;
unfractionated heparin, LMWH; low-molecular weight heparin, *p = 0.001
versus UFH, **p = 0.008 versus UFH, ***p = 0.035 versus UFH, ****p = 0.001
versus THA.
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operative day 7) in each patients with (A) or without (B) seroconvertion of IgG-class anti-PF4/heparin antibodies were shown.
Table 4 Patients characteristics and symptomatic DVT
DVD(-) DVT(+)
Characteristics n = 318 n = 56 p
Age 68.2 ± 11.6 ( 25-90 ) 74.5 ± 7.8 (45-86) <0.00001
Age≧75 yr 106 32 0.001
Age < 75 yr 212 24
Gender(male/female) 60/258 5/51 0.070
BMI(Kg/m
2) 24.7 ± 4.2 (13.7-41.4) 25.8 ± 3.8 (20.1-35.1) 0.088
BMI≧30 37 10 0.195
BMI < 30 281 46
Risk factors 176(55.3%) 38(67.9%) 0.081
TKA/THA 125/193 35/21 0.001
OA/RA 273/46 48/7 0.697
Seroconvertion of IgG-class Anti-PF4/heparin Ab 54(17.0%) 20(35.7%) 0.001
Treatment
UFH 89 (27.7%) 16 (28.6%) 0.890
LMWH 81 (25.5%) 14 (25.0%) 0.940
Fondaparinux 73 (23.0%) 8 (14.3%) 0.146
Others 37 (11.6%) 13 (23.2%)
Aspirin 31 (9.7%) 12 (21.4%)
Warfarin 5 (1.6%) 0
Cilostazol 26 (8.2%) 11 (19.6%)
No medication 39 (12.3%) 5 (8.9%) 0.475
Abbreviations: DVT; deep vein thrombosis; BMI; body mass index, TKA; total knee arthroplasty, THA; total hip arthroplasty, OA; osteoarthritis, RA; rheumatoid
arthritis, UFH; unfractionated heparin, LMWH; low-molecular weight heparin.
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the gold standard in the diagnosis of HIT, they are tech-
nically challenging and few laboratories have the ability
to perform them.
Through the analysis of a large cohort of 374 patients,
we observed that IgG-anti-PF4/heparin antibodies were
frequently detected in patients receiving UFH, as well as
those receiving LMWH or fondaparinux. Furthermore,
seroconversion of the IgG-class anti-PF4/heparin Ab was
an independent risk for symptomatic DVT in these
patients. However, in the sub-analysis seroconversion of
the IgG-class anti-PF4/heparin Ab was not an indepen-
dent risk for symptomatic DVT in patients receiving
LMWHs, fondaparinux or oral anti-coagulants. These
observations suggest that seroconversion of the IgG-class
anti-PF4/heparin Ab could contribute to the thromboem-
bolic complications in patients receiving UFH, and not in
those receiving LMWEs or fondaparinux.
The prevalence of HIT varies between agents and its
range is 1-5% for UFH and 0-0.8% for LMWH [18].
Warkentin et al. reported the seroconversion incidence
of anti-PF4/heparin Ab (fondaparinux 1.4% vs. enoxa-
parin 1.3%) and the incidence of HIT (fondaparinux
0.4% vs. enoxaparin 0.4%) in orthopedic surgery patient
receiving fondaparinux and enoxoparin [9]. In our IgG-
specific immune assay, the proportion that serocon-
verted was 32.6% in patients receiving UFH, 9.5% for
LMWHs and 14.8% for fondaprinux. Although this
study was limited because we did not use functional
assays, these seroconversion rates of IgG-class anti-PF4/
heparin Ab were shown to be relatively high with these
anti-thromboembolic prophylactic therapeutics.
Non-drug factors, including type of surgery, are
thought to play an important role in influencing the
anti-PF4/heparin immune response. Ahamad et al.
reported that anti-PF4/heparin antibody formation was
higher in patients who had undergone total knee arthro-
plasty compared with total hip arthroplasty in clinical
trial comparing UFH and LMWH [19]. More recently,
Warkentin et al. demonstrated that anti-PF4/heparin
antibody formation was more frequently observed after
total knee arthroplasty compared with total hip arthro-
plasty [20]. In our study, in TKA, air tourniquest was
used during operation in all patients. Hemostasis or
local tissue ischemia of lower extremities related to the
use of air tourniquet could partly contribute to the
increased frequencies of IgG-class anti-PF4/heparin anti-
bodies in patients receiving TKA.
It has been suggested that a syndrome resembling HIT
occurs less frequently with fondaparinux [21]. This
hypothesis is based on the concept that the IgG class
anti-PF4/heparin antibodies are generated in fewer
patients receiving fondaparinux [22]. Indeed, our study
indicated that the seroconversion incidence of IgG-class
anti-PF4/heparin antibody was lower in patients receiv-
ing fondaparinux compared with those receiving UFH.
It has been demonstrated that fondaparinux does not
activate platelets in the presence of sera obtained from
patients with HIT, however UFH can activate platelets
in functional platelet activation assays [23]. Also, pre-
vious studies have shown that sera obtained from
patients with HIT containing anti-PF4/heparin antibo-
dies fail to react against PF4 in the presence of fonda-
parinux [9]. These differences may contribute to our
finding that seroconversion of the anti-PF4/heparin anti-
bodies was not an independent risk factor for sympto-
matic DVT in patients receiving fondaparinux. Our
results suggest that IgG-class anti-PF4/heparin antibo-
dies generated in patients receiving fondaprinux were
not able to activate platelets to induce thrombotic
complications.
Our study has potential limitations. We surveyed
symptomatic DVT in patients undergoing TKA or THA
with different antithrombotic prophylaxis therapeutics.
However, we attempted to maintain consistency
Table 5 Multivariate analysis for risk factors of
symptomatic DVT
Variable p HR 95%CI
Age≧75 yr 0.010 2.396 (1.227-4.677)
Male Gender 0.041 0.353 (0.130-0.957)
Risk factors 0.760 1.114 (0.556-2.233)
TKA/THA 0.074 1.792 (0.944-3.401)
Seroconvertion of IgG-class HIT Ab 0.005 2.583 (1.338-4.984)
Abbreviations: DVT; deep vein thrombosis, TKA; total knee arthroplasty, THA;
total hip arthroplasty, HR; Hazard Ratio, CI; Confidence Interval.
Table 6 Comparison of symptomatic DVT incidence
between IgG-class anti-PF4/heparin Ab seroconverted
and non-seroconverted patients
Incidence of symptomatic
DVT (%)
Drug seroconverted non-
seroconverted
Odds ratio
(95%CI)
p
value
UFH 11/34(32.4%) 5/70(7.1%) 6.217 (1.951-
19.816)
0.001
LMWH 3/9(33.3%) 11/86(12.8%) 3.409 (0.743-
15.642)
0.125
Fondaparinux 3/12(25.0%) 5/69(7.2%) 4.267 (0.868-
20.972)
0.092
Others 3/19(15.8%) 15/75(20.0%) 0.750 (0.193-
2.913)
0.481
Abbreviations: DVT; deep vein thrombosis, UFH; unfractionated heparin,
LMWH; low-molecular weight heparin, 95%CI; confidence interval.
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the groups; i.e., all patients who underwent THA or
TKA receiving standardized anticoagulant regimens, and
had the same duration of follow-up. All thrombotic out-
comes were confirmed with objective tests. Thus, we
believe that our results provide valid estimates of the
risk of symptomatic venous thromboembolism in
patients who receive short-duration prophylaxis after
THA or TKA. Another limitation of our study includes
the performance rate of venous doppler US or com-
puted tomography. Therefore, the incidence of DVT in
t h ep r e s e n ts t u d yc a n n o tb ec o m p a r e dt ot h a to fp r e -
vious studies. We surveyed the usage of anti-coagulants
and anti-platelet agents, before and after total joint
arthroplasty (TKA and THA), however, the natural pro-
ducts with anti-thrombotic properties had not been
monitored.
In summary, symptomatic DVT developed in 15.0% of
patients undergoing total joint arthroplasty (TKA and
THA) with various thromboprophylaxis therapeutics.
However, it was determined that the independent risk
factors for DVT are elder-age (≧75 years) and serocon-
version of the IgG-class PF4/heparin antibody. The use
of UFH and TKA was associated with a higher incidence
of IgG-class PF4/heparin antibodies compared with the
use of LMWH or fondaparinux and THA. Furthermore,
seroconversion of the IgG-class PF4/heparin antibody
contributed to the occurrence of DVT more frequently
in patients receiving UFH compared to those receiving
LMWH or fondaparinux. These findings suggest that
seroconversion of IgG-class PF4/heparin antibodies can
be associated with DVT even in the absence of throm-
bocytopenia, in a subset of patients undergoing total
joint arthroplasty (TKA and THA).
Conclusion
Seroconvertion of IgG-class anti-PF4/heparin antibodies
were occurred in a significant number of patients receiv-
ing total joint arthroplasty (TKA and THA) treatments
and their frequencies may depend on anti-thrombotic
p r o p h y l a x i sa g e n t sa n dt y p e so fo p e r a t i o n( T K Ao r
T H A ) .F u r t h e r m o r e ,s e r o c o n v e r t i o no fI g G - c l a s sa n t i -
PH4/heparin antibodies could be an independent risk
factor for symptomatic DVT in these patients.
Abbreviations
DVT: deep vein thrombosis; HIT: heparin-induced thrombocytopenia; LMWH:
low molecular weight heparin; TKA: total knee arthroplasty; THA: total hip
arthroplasty; PE: pulmonary embolism; UFH: unfractionated heparin; VTE:
venous thromboembolism
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